奥妥珠单抗诱导的急性血小板减少症:两例病例报告及文献综述
奥妥珠单抗(GA101)是用于治疗B细胞恶性肿瘤的人源化抗CD20单克隆抗体,罕见情况下可诱导急性严重血小板减少症(OIAT)。本文报告2例OIAT并复习文献,以指导这一罕见但危及生命的并发症的管理与转归。
要点
- 例1为74岁女性初治滤泡性淋巴瘤,奥妥珠单抗-CVP治疗后次日血小板从376 G/L降至3 G/L。
- 例2为44岁女性套细胞淋巴瘤第4线治疗,格菲妥单抗输注前第8天予奥妥珠单抗预处理,次日血小板从76 G/L降至3 G/L。
- OIAT罕见但危及生命,医生应认识该不良事件以优化识别和治疗。
核心结论
- OIAT是罕见但危及生命的并发症,医生应认识该不良事件以优化识别和治疗。
研究设计与样本
- 病例报告2例并复习文献,描述OIAT的管理与转归。
主要发现
- 例1为74岁女性初治滤泡性淋巴瘤,接受奥妥珠单抗-CVP治疗,治疗后次日血小板从376 G/L降至3 G/L。
- 例2为44岁女性套细胞淋巴瘤第4线治疗,格菲妥单抗输注前第8天予奥妥珠单抗预处理,治疗后次日血小板从76 G/L降至3 G/L,此前血小板减少归因于脾大和骨髓受累。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obinutuzumab (GA101) is a humanized anti-CD20 monoclonal antibody used in the treatment of B-cell malignancies. Under rare occasions, obinutuzumab may induce acute and severe thrombocytopenia. However, little is known about this side effect, referred to as "obinutuzumab-induced acute thrombocytopenia" (OIAT). Here, we report 2 cases of OIAT and review the literature to inform the management and outcome of this rare but life-threatening complication. The first case is a 74 year- old woman who was treated with obinutuzumab-Cyclophosphamide, Vincristine, Prednisone (CVP) for a previously untreated follicular lymphoma. This patient experienced an acute thrombocytopenia with a drop in her platelet count from 376 G/L to 3 G/L the day after treatment. The second case is a 44 year- old woman who was treated with obinutuzumab as a pre-treatment dose (day-8) before glofitamab infusion as a 4th line therapy for mantle cell lymphoma. This patient experienced an acute thrombocytopenia with a drop in her platelet count from 76 G/L (due to splenomegaly and bone marrow involvement) to 3 G/L the day after treatment. OIAT is a rare but life-threatening complication. Physicians should be aware of this adverse event to optimally detect and treat this complication.
引用
- Mechelfekh Y, Pontrucher A, Paillassa J, et al. Obinutuzumab-induced acute thrombocytopenia: Report of two cases and review of literature. Br J Haematol. 2023. PMID: 37143375. doi:10.1111/bjh.18826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。